Evidence map›Paper›PMID 38297203›Full record

SynthesisBMC genomic data2024

BRCA 1/2 mutations and risk of uterine cancer: a systematic review and meta-analysis.

Faezeh Zakerinasab, Qumars Behfar, Reza Parsaee, Reza Hossein Zadeh, Elaheh Foroughi, Amirhesam Amirbeik, Ghazalehsadat Ahmadi

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC genomic data, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Faezeh ZakerinasabMashhad University of Medical Sciences, Mashhad, Iran.
Qumars BehfarDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Reza ParsaeeMaster Student in Molecular Genetics, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Reza Hossein ZadehStudent's Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Elaheh ForoughiSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Amirhesam AmirbeikStudent Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ghazalehsadat AhmadiMashhad University of Medical Sciences, Mashhad, Iran. Ghazale_6053@yahoo.com.
Mashhad University of Medical Sciences · IRIsfahan University of Medical Sciences · IRShiraz University of Medical Sciences · IRUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn this study, we aim to investigate the association between BRCA1/2 mutation and uterine cancer incidence. MATERIAL AND

methodWe systematically searched three databases including PubMed, Scopus, and Google Scholar up to August 2023; and reviewed 23 cohorts and cross-sectional studies to explore the association between BRCA1/2 mutations and uterine cancer incidence.

resultsThis systematic review comprised a total of 21 cohort studies and 2 cross-sectional studies after the screening process. According to meta-analysis the prevalence of the BRCA1/2 gene in patients with uterine cancer was 0.02 (95%CI = [0.01,0.03], P < 0.01, I

Indexed as

BRCA1 ProteinBRCA2 ProteinUterine NeoplasmsCross-Sectional StudiesFemaleHumansMutationBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1BRCA2EndometrialMutationUterine cancer

Identifiers

PMID38297203
PMCPMC10829221
OpenAlexW4391390109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.